HER-2 is a proto-oncogene located at 17q21 that encodes a 185-kd transmembrane glycoprotein with tyrosine kinase activity. HER-2 (also known as c-erbB-2 or neu) is a member of the epidermal growth factor receptor family and is now recognized as a key oncogene in several malignancies.
HER2 gene amplification is the primary mechanism for HER2 overexpression which occurs in 18–20% of invasive breast cancer. It is regarded as a marker of adverse clinical outcome and as a predictive marker for reduced response to certain chemotherapy and hormonal treatments. Even more importantly, positive HER-2 status predicts for response to therapy with trastuzumab (Herceptin), which is effective in prolonging patient’s survival with receptor positive metastatic breast carcinoma.
Thus reliable and robust method for determining Her2 status in breast carcinomas has a clinical benefit.
Mylab Discovery Solutions provides quantitative real-time PCR assay for detection of HER2 DNA amplification. The HER2 gene is amplified in parallel with a reference gene in a single tube and the copy-number ratio between HER2 and the reference gene is analysed. It is very simple, sensitive, reproducible method for HER2 detection and quantitation.